Epistem (AIM: EHP), the biotechnology and personalised medicine company, today announces a pre-close trading statement for the year ended 30th June 2011.
Following a positive year during which all the Company's business units made good progress, the Company is pleased to announce that trading over the full year is expected to be profitable and broadly in-line with market forecasts.
The Company expects to release its final results for the year ended 30th June 2011 on Tuesday 11th October 2011 and will hold an analysts' meeting on the day at Peel Hunt LLP, 111 Old Broad Street, London EC2N 1PH.
The Company also announces that, with immediate effect, Dr. Gerard Brady will be stepping down from the Epistem Board. The Company will continue to benefit from Ged's experience as he will join the Scientific Advisory Board in his new role as scientific adviser to the Company.
For further information contact:
Matthew Walls, Chief Executive Officer ++44 161 606 7258
John Rylands, Chief Financial Officer
Peel Hunt LLP
Nominated Adviser: James Steel/Vijay Barathan ++44 207 418 8900
De Facto Financial
Mike Wort/Anna Dunphy ++44 207 556 1063
Notes for editors
Epistem is a biotechnology and personalised medicine company commercialising its expertise in epithelial stem cells in the areas of oncology, gastrointestinal and dermatological diseases. Epistem develops innovative therapeutics, biomarkers and diagnostics alongside providing contract research services to drug development companies. The Group's core expertise is focused on the regulation of adult stem cells located in epithelial tissue, which includes the gastrointestinal tract, skin, hair follicles, breast and prostate.
This information is provided by RNS
The company news service from the London Stock Exchange
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.